• Signed master service agreement with Sabra, covering 350 US aged care homes and 20,000 beds
• Contracted licences grew to 118,577 globally, with 85,200 implemented
• Continued strong growth in UK, with 4,000 new licences

PainChek Ltd (ASX: PCK) has reported a strong quarter, with key highlights including signing a master service agreement with Nasdaq-listed healthcare REIT Sabra, covering 350 US aged care homes and an opportunity of 20,000 beds with A$2M in annual recurring revenue (ARR). The company also grew its contracted licences globally to 118,577 across more than 2,000 aged care facilities, with an ARR of $5.9m once fully implemented, a 7% increase on the prior quarter. Implemented licences grew to 85,200 globally, an increase of 16% primarily in ANZ and the UK. In the UK, the company added 4,000 new licences. PainChek also reported cash reserves of $2.3m, an expected R&D tax incentive of $1.1m, and continued progress on its infant product and US reimbursement initiatives. The company highlighted strong growth in its North American, ANZ, and UK markets, driven by new customer wins, integration partnerships, and favourable reimbursement developments.

The company expects to see further traction across its numerous market opportunities through the rest of the year, with the Sabra agreement providing access to up to 36,000 beds across 329 facilities, of which 20,000 (ARR $2M) are applicable to PainChek.

PainChek is well-positioned to accelerate adoption through a combination of direct sales, channel partnerships, and an increasingly favourable reimbursement environment across North America. The company also continues to refine its Infant app and build targeted healthcare professional channels to drive recommendation, awareness, and uptake in Australia, with plans to expand overseas in early 2027.